MONMOUTH JUNCTION, N.J., March 27, 2017 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the selection of its REFRESH I cardiac surgery  “Late-Breaking Clinical Trial” abstract for podium presentation at the American Association for Thoracic Surgery (AATS) Centennial Conference in Boston, April 29 – May 3, 2017.

Dr. Robert Bartlett, Chief Medical Officer of CytoSorbents, stated, “The competitive selection of our REFRESH I abstract by an independent scientific review committee for presentation validates the clinical importance of treating uncontrolled inflammation during cardiac surgery and the potential of our CytoSorb blood purification approach.”

AATS Centennial Conference

  • Session Name: Perioperative Care Simultaneous Scientific Session
  • Title of Presentation: “Use of a Novel Hemoadsorption Technology to Reduce Plasma Free Hemoglobin during Complex Cardiac Surgery: Results from the Randomized Controlled Safety and Feasibility REFRESH I Trial”
  • Presenter: Dr. Thomas G. Gleason, MD, Chief – Division of Cardiac Surgery and Ronald V. Pellegrini Endowed Professor of Cardiothoracic Surgery, University of Pittsburgh School of Medicine
  • Where:  Room 306, Hynes Convention Center, Boston, MA
  • When: Monday, May 1, 2017, between 2:00-5:15PM

About the American Association for Thoracic Surgery

The American Association for Thoracic Surgery is an international organization of over 1,300 of the world’s foremost cardiothoracic surgeons representing 41 countries. Founded in 1917, its members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease throughout the world.  In 2017, the Association will commemorate its 100th Anniversary at this year’s AATS Centennial Conference.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 43 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) I trial – a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery.  In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.  CytoSorb® has been used safely in more than 20,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending worldwide, including CytoSorb-XL, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter

Cytosorbents Contact:
Amy Vogel

Investor Relations

(732) 398-5394

avogel@cytosorbents.com

 

Public Relations Contact:

Amy Phillips     
Pascale Communications     
412-327-9499     
amy@pascalecommunications.com

  

 

SOURCE CytoSorbents Corporation